Selexipag shows promise for treating pulmonary arterial hypertension associated with connective tissue disease (CTD). The ongoing EXPOSURE (EUPAS19085) study sheds light on the real-world management of PAH-CTD patients in Europe and Canada.
For more detailed insights, check out the full study results at this link on PubMed
Citation
Gaine S, Escribano-Subias P, Muller A, Fernandes CC, Fontana M, Remenova T, Söderberg S, Lange TJ. Selexipag in patients with pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD): Real-world experience from EXPOSURE. Pulm Circ. 2024 Jul 28;14(3):e12403. doi: 10.1002/pul2.12403. PMID: 39076250; PMCID: PMC11284239.